People
Elizabeth F. Lindquist is a partner in the FDA & Life Sciences Practice in King & Spalding’s Washington, D.C., office. She counsels life sciences companies and academic institutions on a broad range of regulatory, compliance, enforcement, litigation, and debarment matters relating to federal health care agencies, programs, contracts, and grants, including the Department of Veterans Affairs Federal Supply Schedule Program, the Centers for Medicare & Medicaid Services, the Health Resources and Services Administration, the U.S. Department of Defense's TRICARE Program, and the National Institutes of Health. Elizabeth also has significant experience advising pharmaceutical and biotechnology manufacturers on complex regulatory and compliance issues related to government price calculation and reporting practices.
Elizabeth specializes in the U.S. federal government’s procurement of pharmaceuticals, medical devices and supplies, and services, including contract and grant bid submission, negotiation, and compliance, novation and assignment of claims, teaming agreement, subcontracting, country-of-origin, enforcement, and clinical research issues. She also advises financial institutions and investors on transactions involving federal contractors.
Elizabeth graduated from the Saint Louis University School of Law in 2009, where she received a Dean’s Scholarship, a Certificate in Health Law Studies, and was the Editor-in-Chief of the Saint Louis University Journal of Health Law & Policy. Elizabeth graduated from Williams College in 2005 with a Bachelor of Arts with Honors in Biology and History. At Williams, Elizabeth completed an Honors thesis in Biology and was an All-American softball player.
Prior to attending law school, Elizabeth worked as a Clinical Research Coordinator at the Hospital for Special Surgery in New York, New York. In this position she ensured that clinical research protocols complied with Institutional Review Board requirements and all applicable federal and state laws and regulations. Elizabeth also gained experience filing regulatory submissions with the FDA and served as the liaison between clinical investigators and the Hospital’s Legal Department.
J.D., Saint Louis University
B.A., Williams College, with honors
Colorado
District of Columbia
New York
August 7, 2020
Elizabeth Lindquist comments on a new Trump executive order mandating that the government purchase critical drugs domestically
April 15, 2019
Twelve King & Spalding Attorneys to Serve on 2019 Law360 Editorial Advisory Boards
March 2, 2021
White House Invokes the Defense Production Act to Accelerate Johnson & Johnson Vaccine Production
February 5, 2021
White House COVID-19 Response Team Discusses Use of DPA
December 31, 2020
Final Rule on VBP, Patient Assistance and Line Extensions Presents Opportunity and Risk for Drug Manufacturers
August 7, 2020
Elizabeth Lindquist comments on a new Trump executive order mandating that the government purchase critical drugs domestically
April 15, 2019
Twelve King & Spalding Attorneys to Serve on 2019 Law360 Editorial Advisory Boards
March 2, 2021
White House Invokes the Defense Production Act to Accelerate Johnson & Johnson Vaccine Production
February 5, 2021
White House COVID-19 Response Team Discusses Use of DPA
December 31, 2020
Final Rule on VBP, Patient Assistance and Line Extensions Presents Opportunity and Risk for Drug Manufacturers
August 7, 2020
Elizabeth Lindquist comments on a new Trump executive order mandating that the government purchase critical drugs domestically
April 15, 2019
Twelve King & Spalding Attorneys to Serve on 2019 Law360 Editorial Advisory Boards
J.D., Saint Louis University
B.A., Williams College, with honors
Colorado
District of Columbia
New York